Stoke Therapeutics CEO Kaye steps down; Ian Smith named interim; FY 2024 net loss $89M

Stoke Therapeutics, Inc.

CEO Edward Kaye steps down March 19; Ian F. Smith appointed Interim CEO; Arthur Tzianabos named Interim Executive Chair.
Full year 2024 net loss $89.0M ($1.65/share) vs $104.7M loss in 2023; revenue $36.6M from Acadia collaboration (vs $8.8M prior year).
Cash, equivalents, and marketable securities $246.7M at Dec 31, 2024; plus $165M upfront from Biogen collaboration funds operations to mid-2028.
Phase 3 registrational study (EMPEROR) of zorevunersen for Dravet syndrome on track to initiate in Q2 2025.
Board initiates search for permanent CEO; Kaye remains as advisor and director.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Edward Kaye

Chief Executive Officer

STOK · Stoke Therapeutics, Inc.

Effective: 2025-03-19
Successor: Ian F. Smith
Filed: March 18, 2025, 7:59 PM ET

On March 16, 2025, Dr. Edward Kaye, M.D., 75, the Company’s Chief Executive Officer (“CEO”) and a director, informed the Company’s Board of Directors (the “Board”) of his intention to step down from his position as the Company’s CEO, effective March 19, 2025 (the “Transition Date”).

Appointed (interim)

Arthur Tzianabos

Interim Executive Chair

STOK · Stoke Therapeutics, Inc.

Effective: 2025-03-19
Filed: March 18, 2025, 7:59 PM ET

Also in connection with Dr. Kaye’s transition, effective as of the Transition Date, the Board appointed Arthur Tzianabos, 61, currently Chair of the Board, as Interim Executive Chair of the Board.

Appointed (interim)

Ian F. Smith

Interim Chief Executive Officer

STOK · Stoke Therapeutics, Inc.

Effective: 2025-03-19
Filed: March 18, 2025, 7:59 PM ET

Effective as of the Transition Date, the Board appointed Ian F. Smith, 59, a director on the Board, to succeed Dr. Kaye as Interim Chief Executive Officer (“Interim CEO”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Edward Kaye departed as Chief Executive Officer at Stoke Therapeutics, Inc..

Action: stepped down
Role: Chief Executive Officer

Exact text from the filing

On March 16, 2025, Dr. Edward Kaye, M.D., 75, the Company’s Chief Executive Officer (“CEO”) and a director, informed the Company’s Board of Directors (the “Board”) of his intention to step down from his position as the Company’s CEO, effective March 19, 2025 (the “Transition Date”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Arthur Tzianabos was appointed as Interim Executive Chair at Stoke Therapeutics, Inc..

Action: appointed
Role: Interim Executive Chair

Exact text from the filing

Also in connection with Dr. Kaye’s transition, effective as of the Transition Date, the Board appointed Arthur Tzianabos, 61, currently Chair of the Board, as Interim Executive Chair of the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Ian F. Smith was appointed as Interim Chief Executive Officer at Stoke Therapeutics, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

Effective as of the Transition Date, the Board appointed Ian F. Smith, 59, a director on the Board, to succeed Dr. Kaye as Interim Chief Executive Officer (“Interim CEO”).

View on SEC.gov

Stoke Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-040758

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.